1. Home
  2. NUVL vs ESNT Comparison

NUVL vs ESNT Comparison

Compare NUVL & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.50

Market Cap

9.8B

Sector

Health Care

ML Signal

HOLD

Logo Essent Group Ltd.

ESNT

Essent Group Ltd.

HOLD

Current Price

$63.91

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
ESNT
Founded
2017
2008
Country
United States
Bermuda
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.8B
5.9B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
NUVL
ESNT
Price
$123.50
$63.91
Analyst Decision
Strong Buy
Buy
Analyst Count
16
7
Target Price
$134.75
$67.29
AVG Volume (30 Days)
4.2M
858.9K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
2.19%
EPS Growth
N/A
0.73
EPS
N/A
1.82
Revenue
N/A
$1,260,935,000.00
Revenue This Year
N/A
$1.12
Revenue Next Year
$1,239.49
$3.37
P/E Ratio
N/A
$33.97
Revenue Growth
N/A
1.45
52 Week Low
$71.14
$55.22
52 Week High
$123.69
$67.09

Technical Indicators

Market Signals
Indicator
NUVL
ESNT
Relative Strength Index (RSI) 66.42 65.52
Support Level $97.99 $62.44
Resistance Level $123.62 $63.78
Average True Range (ATR) 0.58 1.20
MACD 0.66 0.62
Stochastic Oscillator 99.45 92.95

Price Performance

Historical Comparison
NUVL
ESNT

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About ESNT Essent Group Ltd.

Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.

Share on Social Networks: